코디악 사이언시즈(KOD)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $32.71 (-0.43%), 시가총액 $2.32B, 52주 최저~최고 $3.40 ~ $46.44.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- inte
코디악 사이언시즈의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
코디악 사이언시즈의 현재 주가는 $32.71 (-0.43%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
코디악 사이언시즈의 시가총액은 약 $2.32B입니다.
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is t